- ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkins Lymphoma: A Single Center Experience
-
Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP, Huh J, Kim SB, Kim SW, Lee JL, Suh C
- KMID: 759841
- Korean J Intern Med.
- 2006 Sep;21(3):159-164.
- doi: 10.3904/kjim.2006.21.3.159
BACKGROUND: The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma... -
- CITED
-
- Close
- SHARE
-
- Close
- Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
-
Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS
- KMID: 1785660
- Korean J Intern Med.
- 2010 Mar;25(1):86-92.
- doi: 10.3904/kjim.2010.25.1.86
BACKGROUND/AIMS: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus... -
- CITED
-
- Close
- SHARE
-
- Close
